Randomized Study Comparing BudesonideAlbuterol and Albuterol Inhalers in Adolescents 12 to Under 18 Years with Asthma Over 52 Weeks
Led by AstraZeneca · Updated on 2026-10-13
440
Participants Needed
155
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year.
Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler.
During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.
CONDITIONS
Brief Title
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
BDA MDI as needed
AS MDI as needed
What it is
Metered‑dose inhaler combining budesonide and albuterol given as needed on top of existing maintenance therapy
Metered‑dose inhaler of albuterol given as needed in addition to maintenance therapy
Role in trial
Investigational treatment being tested for efficacy and safety
Active comparator arm using albuterol alone
Primary use
Used as needed to relieve asthma symptoms and potentially reduce severe exacerbations
Used as needed to relieve asthma symptoms and monitor baseline exacerbation rate
How it is given or performed
Participants inhale 2 puffs of the combination budesonide/albuterol MDI 160/180 µg as needed
Participants inhale 2 puffs of albuterol MDI 180 µg as needed
Evidence status
Efficacy and safety are being evaluated in this trial; adult data suggest 27 % reduction in severe exacerbations with as‑needed budesonide/albuterol
As‑needed albuterol alone serves as a control to compare exacerbation outcomes
Important risks
Safety profile in adolescents is being assessed; adult studies have not demonstrated new safety signals
Albuterol is generally well tolerated but overuse may lead to tolerance or reduced effectiveness
Important limitations
Effects in adolescents are extrapolated partially from adult data using Bayesian borrowing; results pending
Comparator reflects real‑world reliever use but does not address maintenance regimen impacts
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 12Years - 17Years
All Genders
Eligibility Criteria
You may qualify if you...
Confirmed clinical diagnosis of asthma for at least 12 months
Age between 12 and 17 years
Receiving stable asthma maintenance therapy with inhaled corticosteroids or inhaled corticosteroids plus long-acting beta2-agonists for at least 3 months
Using inhaled short-acting beta2-agonist as needed
History of at least one severe asthma exacerbation within 12 months
Use of sponsor-provided albuterol inhaler
Ability to properly use metered-dose inhaler without spacers
Ability to perform reproducible peak expiratory flow measurements
Adherence to protocol-specific contraception methods
Negative urine pregnancy test for participants of childbearing potential
Body mass index less than 40 kg/m2
Able to give assent and have caregiver provide consent
You will not qualify if you...
History of life-threatening asthma episodes requiring intubation or associated with serious complications
More than 3 severe asthma exacerbations within 12 months before screening
Recent treatment with systemic corticosteroids for respiratory infection or severe asthma exacerbation within 4 weeks prior to screening
Current smokers or former smokers with more than 10 pack-years or who quit less than 6 months ago
Other significant lung diseases or regular oxygen use
Significant other diseases including cardiovascular, liver, kidney, blood, neurological, endocrine, or gastrointestinal disorders
Cancer not in remission for at least 5 years
Recent hospitalization for psychiatric disorders or suicide attempts within one year
Significant alcohol or drug abuse
Use of oral corticosteroids within 4 weeks before study start or chronic use in prior 3 months
Use of oral short-acting beta2-agonists within one month
Known or suspected allergy to albuterol, budesonide, or inhaler components
Your Study Journey
Screening
Duration - 7 to 28 days
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 52 weeks
Participants use either the budesonide/albuterol inhaler or the albuterol inhaler as needed along with their usual asthma maintenance therapy.
Regular visits throughout treatment period
Safety Follow-up
Duration - 7 to 14 days
Participants are monitored for safety for 7 to 14 days after completing treatment.
1 visit (in-person)
Pharmacokinetic Sub-study
Duration - 1 day
Participants in the sub-study receive a single dose of the budesonide/albuterol inhaler and have drug levels measured at one visit after safety follow-up.
1 visit (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 4 Multicenter Study on Starting Airsupra in the Emergency Department to Improve Asthma Outcomes Compared to Usual Care
Study of Inflammatory Lung Diseases Including Asthma, COPD, Bronchiectasis, Cystic Fibrosis, PCD, and ILD to Understand Patient Characteristics and Improve Personalized Treatment
Phase 1 Randomized Study Comparing Pharmacokinetics of Two GSK5784283 Formulations in Healthy Adults by Injection
Evaluating Different Lung Function Tests Including Impulse Oscillometry for Diagnosing Asthma in Adults
Evaluating Two Doses of Glycopyrronium Inhaler Compared to Placebo with Budesonide and Formoterol in Children 4 to Under 12 Years with Asthma
Randomized Feasibility Study of Nocturnal CPAP Compared to Standard Care in Adults with Large Airway Collapse
Study to Assess Patient Characteristics and Outcomes in Asthma Across Different Severities in Real-World Care
A Cross-Sectional and Prospective Observational Study of Asthma Disease Burden and Control
Phase 3 Open-label Study to Assess Depemokimab as Add-on Treatment for Asthma with Type 2 Inflammation in Children Aged 6 to 11 Years
Evaluating Depemokimab as an Add-On Treatment for Adolescents and Adults with Type 2 Asthma at Risk of Exacerbations Compared to Placebo and Standard Care
Evaluating HB0056 Injection for Adults with Moderate to Severe Asthma
Randomized, Double-Blind, Placebo-Controlled Study of Safety and Effectiveness
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial.
Leonard Benjamin Bacharier, Hengameh Raissy, Samuel Bardsley...